Supplement to: Burden of SARS-CoV-2 and Protection from Symptomatic Secondary Infection in Children

#### **Table of Contents:**

Page 3) Case definitions

Page 4) Supplemental Table 1: Incidence of COVID-19 Associated Hospitalization

Page 5) Supplemental Table 2: Symptom presentation of COVID-19 cases by age

Page 6) Supplemental Table 3: Risk of moderate or severe COVID-19 by sero-status

Page 6) Supplemental Table 4: SARS-CoV-2 Illness Severity

Page 7) Supplemental Figure 1: IgG titers by sex

Page 8) Supplemental Figure 2: Incidence rate ratios of COVID-19 associated hospitalization

#### **Case Definitions:**

Term		Definition				
COVID-19 case		RT-PCR positive for SARS-CoV-2 and no prior positive within previous 59 days				
Primary episode		RT-PCR-confirmed case of COVID-19 in participant with no prior positive via				
		PCR or ELISA				
		OR				
		RT-PCR-confirmed case of COVID-19 in participant with prior ELISA positive				
		AND				
		age <6 months at time of ELISA positive				
Secondary episode		RT-PCR-confirmed case of COVID-19 in participant with prior ELISA positive				
		AND				
		age $\geq$ 6 months at time of ELISA positive				
		OR				
		RT-PCR-confirmed case of COVID-19 in participant with prior RT-PCR-				
	T =	confirmed case of COVID-19 occurring >59 days prior.				
Severity	Subclinical	No reported symptoms				
	Mild	1 or more of the following symptoms:				
		• loss of taste				
		• loss of smell				
		• runny nose				
		• cough				
		• headache				
		sore throat				
		• joint pain				
		• fever				
		muscle pain				
		diarrhea				
		• fatigue				
		• rash				
		stayed in bed				
		conjunctivitis				
Moderate  Severe		• congestion				
		• itchy throat				
		• loss of appetite				
		• faintness				
		• tight chest				
		• chest pain				
		Any of the following symptoms:				
		difficulty breathing				
		• rapid breathing				
		• shortness of breath				
		Transfer to hospital				
Long COVID		Participants with any symptom persisting for at least 28 days following illness				
2019 00 112		onset for confirmed COVID-19				

## **Supplemental Table 1: Incidence of COVID-19 Associated Hospitalization**

Characteristi	ic	N=12	Incidence Rate per 100 person-years
Male		7(58.3)	0.5 (0.2, 1.1)
Female		5(41.7)	0.4 (0.1, 0.9)
Age	<2 years	7(58.3)	1.7 (0.7, 3.5)
	2-4 years	3(25.0)	0.6 (0.1, 1.6)
	5-9 years	2(16.7)	0.2 (0.03, 0.8)
	10-14 years	0	
<sup>a</sup> Confidence in	ntervals calculated using Po	isson distribution.	

Supplemental Table 2: Symptom presentation of COVID-19 cases by age

Characteristic	<2 years, N = 66 <sup>a</sup>	2-4 years, N = 30 <sup>a</sup>	5-9 years, N = 52 <sup>a</sup>	10-14 years, N = 59 <sup>a</sup>	Overall, N = 207 <sup>a</sup>
Loss of taste	0 (0)	0 (0)	3 (5.8)	8 (14)	11 (5.3)
Loss of smell	0 (0)	0 (0)	3 (5.8)	11 (19)	14 (6.8)
Runny nose	48 (73)	26 (87)	37 (71)	44 (75)	155 (75)
Cough	48 (73)	23 (77)	36 (69)	41 (69)	148 (71)
Headache	0 (0)	6 (20)	24 (46)	37 (63)	67 (32)
Sore throat	3 (4.5)	7 (23)	26 (50)	28 (47)	64 (31)
Fever/feverish	46 (70)	20 (67)	35 (67)	38 (64)	139 (67)
Joint pain	0 (0)	1 (3.3)	3 (5.8)	14 (24)	18 (8.7)
Muscle pain	0 (0)	2 (6.7)	6 (12)	15 (25)	23 (11)
Diarrhea	19 (29)	3 (10)	10 (19)	6 (10)	38 (18)
Vomiting	5 (7.6)	0 (0)	4 (7.7)	3 (5.1)	12 (5.8)
Fatigue	0 (0)	0 (0)	0 (0)	1 (1.7)	1 (0.5)
Rash	1 (1.5)	1 (3.3)	0 (0)	1 (1.7)	3 (1.4)
Stayed in bed	0 (0)	0 (0)	1 (1.9)	1 (1.7)	2 (1.0)
Conjunctivitis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Congestion	30 (45)	14 (47)	23 (44)	23 (39)	90 (43)
Itchy throat	1 (1.5)	0 (0)	3 (5.8)	5 (8.5)	9 (4.3)
Loss of appetite	15 (23)	11 (37)	17 (33)	7 (12)	50 (24)
Fainted	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Difficulty breathing	3 (4.5)	2 (6.7)	4 (7.7)	3 (5.1)	12 (5.8)
Rapid breathing	4 (6.1)	1 (3.3)	2 (3.8)	0 (0)	7 (3.4)
Shortness of breath	0 (0)	0 (0)	1 (1.9)	2 (3.4)	3 (1.4)
Chest tightness	1 (1.5)	0 (0)	0 (0)	1 (1.7)	2 (1.0)
Chest pain	0 (0)	0 (0)	0 (0)	3 (5.1)	3 (1.4)
<sup>a</sup> N(%)					

### Supplemental Table 3: Risk of moderate or severe COVID-19 by sero-status


	N=10	Person-years	IRR <sup>a</sup>
Seropositive	5	578.2	0.9 (0.3, 3.2)
Seronegative	5	515.1	
<sup>a</sup> Incidence Rate Ratio (959	% confidence interval)		

#### Supplemental Table 4: SARS-CoV-2 Illness Severity

Characteristic		Subclinical	Mild	Moderate	Severe	Total
Female		409 (73.6)	131 (23.6)	11 (2.0)	5 (0.9)	556
Male		382 (74.5)	112 (21.8)	12 (2.3)	7 (1.4)	513
Age	<2 years	128 (65.3)	58 (29.6)	3 (1.5)	7 (3.6)	196
	2-4 years	148 (79.6)	32 (17.2)	3 (1.6)	3 (1.6)	186
	5-9 years	254 (77.2)	65 (19.8)	8 (2.4)	2 (0.6)	329
	10-14 years	261 (72.9)	88 (24.6)	9 (2.5)	0 (0.0)	358
Total		791 (74.0)	243 (22.7)	23 (2.2)	12 (1.1)	1069

<sup>&</sup>lt;sup>1</sup> Values correspond to N(%)

# Supplemental Figure 1: Anti SARS-CoV-2 IgG titers by sex



### Supplemental Figure 2: Incidence rate ratios of COVID-19 associated hospitalization

